How to buy Cue Biopharma stock (CUE)

Cue Biopharma is a biotechnology business based in the US. Cue Biopharma shares (CUE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.04 – a decrease of 1.89% over the previous week. Cue Biopharma employs 53 staff and has a trailing 12-month revenue of around $8.3 million.

Our top picks for where to buy Cue Biopharma stock

Buy Cue Biopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cue Biopharma stock price (NASDAQ: CUE)

Use our graph to track the performance of CUE stocks over time.

Cue Biopharma shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$1.04
52-week range	$0.45 - $3.20
50-day moving average more info button	$1.32
200-day moving average more info button	$1.28
Wall St. target price	$3.60
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.91

Is it a good time to buy Cue Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cue Biopharma price performance over time

Historical closes compared with the close of $1.01 from 2024-12-20

1 week (2024-12-16)	-0.98%
1 month (2024-11-22)	-0.98%
3 months (2024-09-23)	110.77%
6 months (2024-06-21)	-25.19%

1 year (2023-12-22)	-66.22%
2 years (2022-12-23)	-63.27%
3 years (2021-12-23)	12.44
5 years (2019-12-23)	17.15

Cue Biopharma financials

Revenue TTM	$8.3 million
Gross profit TTM	$1.2 million
Return on assets TTM	-52.11%
Return on equity TTM	-138.87%
Profit margin	0%
Book value	$0.79
Market Capitalization more info button	$67.8 million

TTM: trailing 12 months

Cue Biopharma share dividends

We're not expecting Cue Biopharma to pay a dividend over the next 12 months.

Cue Biopharma share price volatility

Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $0.45 up to $3.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.796. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cue Biopharma overview

Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co. , Ltd.

Frequently asked questions

null
What percentage of Cue Biopharma is owned by insiders or institutions?
Currently 0.549% of Cue Biopharma shares are held by insiders and 23.595% by institutions. How many people work for Cue Biopharma?
Latest data suggests 53 work at Cue Biopharma. When does the fiscal year end for Cue Biopharma?
Cue Biopharma's fiscal year ends in December. Where is Cue Biopharma based?
Cue Biopharma's address is: 40 Guest Street, Boston, MA, United States, 02135 What is Cue Biopharma's ISIN number?
Cue Biopharma's international securities identification number is: US22978P1066 What is Cue Biopharma's CUSIP number?
Cue Biopharma's Committee on Uniform Securities Identification Procedures number is: 22978P106